AngioDynamics Posts Record FY2026 Revenue, 18% Med Tech Growth, and Issues FY2027 Outlook

summarizeSummary

AngioDynamics delivered record FY2026 revenue of $320.2M (+9.4% pro forma), with Med Tech up 18.4%, achieved positive adjusted EBITDA, and guided FY2027 revenue to $336–$341M, projecting continued Med Tech growth and stable margins.

check_boxKey Events · Earnings and Guidance · ANGO

• Record FY2026 Revenue

  Pro forma net sales reached $320.2 million, a 9.4% year-over-year increase, as the Med Tech segment surged 18.4% to $150.0 million and Med Device rose 2.5% to $170.2 million.

• Profitability Milestone

  Full-year adjusted EBITDA turned positive at $13.2 million, and the company generated $3.1 million in cash from operations, ending the period with $53.9 million in cash and no debt.

• FY2027 Guidance Issued

  Management expects net sales of $336–$341 million, Med Tech growth of 12–15%, flat Med Device sales, gross margin of 54–55%, and adjusted EBITDA of $13–$16 million.

• Clinical & Regulatory Catalysts

  The FDA approved the IDE for the RELIEF study evaluating NanoKnife for BPH; two-year PRESERVE data demonstrated durable prostate cancer outcomes; and Medicare LCD and CPT codes now cover NanoKnife in prostate and liver procedures.

auto_awesomeAnalysis · ANGO · Industrial Applications And Services

A record fiscal 2026 saw pro forma revenue climb 9.4% to $320.2 million, fueled by an 18.4% surge in the higher-margin Med Tech segment. The company reached a critical inflection point with positive adjusted EBITDA of $13.2 million and $3.1 million in operating cash flow, signaling a shift toward self-funding operations. Looking ahead, FY2027 guidance targets total revenue of $336–$341 million—a 5–6% increase—with Med Tech expanding 12–15% and gross margins holding steady at 54–55%. While the bottom line remains GAAP-negative with an adjusted loss per share of $0.24, the results and outlook underscore the strategic pivot to faster-growing, higher-margin platforms. A series of clinical and regulatory catalysts—including FDA IDE approvals for the RELIEF, APEX-Return, and PAVE studies, plus Medicare coverage for NanoKnife—further strengthen the pipeline for sustained Med Tech momentum.